Reneo Pharmaceuticals
在场
是其中之一......
Reneo Pharmaceuticals 是一家在股票代码 RPHM (US) 下上市的公司。
涉及Reneo Pharmaceuticals的并购和融资。
- Reneo Pharmaceuticals and OnKure have merged (公布2024十月4号)..
高管
查看带有其 15 名主要高管的组织结构图
Reneo Pharmaceuticals 搜索最多的简介
- Gregory Flesher, President, Chief Executive Officer and Director
- Stacey Seltzer, Director
- Niall O'Donnell, Director
创建提醒
跟踪 Reneo Pharmaceuticals 的高管变动
生物技术
Reneo Pharmaceuticals 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
Reneo Pharmaceuticals 的最新新闻稿
- Reneo Pharma News powered by B2i Technologies - SmartWireReneo Pharma News powered by B2i Technologies - SmartWire
- News - Reneopharma
- News - Reneopharma
- Reneo Pharmaceuticals, Inc. - Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals, Inc. - Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Reneo Pharmaceuticals, Inc. - Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- Reneo Pharmaceuticals, Inc. - Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
- Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
- Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- View more press releases Close
通过电子邮件
